![]() |
市場調査レポート
商品コード
1379188
出生前・新生児遺伝子検査市場レポート:製品タイプ、スクリーニング、疾患、エンドユーザー、地域別、2023-2028年Prenatal and Newborn Genetic Testing Market Report by Product Type, Screening, Disease, End User, and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
出生前・新生児遺伝子検査市場レポート:製品タイプ、スクリーニング、疾患、エンドユーザー、地域別、2023-2028年 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2~3営業日
|
世界の出生前・新生児遺伝子検査の市場規模は、2022年に53億米ドルに達しました。今後、IMARC Groupは、同市場が2028年までに112億米ドルに達し、2022年から2028年にかけて13.3%の成長率(CAGR)を示すと予測しています。先進的な診断・スクリーニング機器に対する需要の高まり、世界中の新生児における先天奇形や遺伝子異常の有病率の上昇、医療産業の隆盛などが、市場を牽引する主要因のひとつです。
出生前・新生児遺伝子検査は、血液検査、特定の種類の超音波検査、出生前無細胞DNAスクリーニングで構成され、胎児や新生児の遺伝子構成に関する貴重な洞察を提供します。この検査は、胎児や新生児の遺伝的障害である特定の先天性異常を特定することができます。この検査は、妊婦の両親、ヘルスケア専門家、調査研究者に重要な情報を提供し、乳児の健康と幸福について十分な情報に基づいた判断を可能にします。妊娠中や乳幼児期の遺伝的変異や異常を正確に同定できるようにする一方で、患者の転帰を改善し、医療介入を導くのに役立ちます。また、ダウン症候群、嚢胞性線維症、鎌状赤血球症、フェニルケトン尿症などの様々な先天性疾患の検出にも役立ちます。両親の血液中の様々なタンパク質レベルを分析し、赤ちゃんの染色体数異常のリスクを判断するのに役立つため、出生前・新生児遺伝子検査の需要は世界中で高まっています。
現在、世界中の大衆の間で高度な診断およびスクリーニング機器に対する需要が高まっていることは、市場の成長を支える重要な要因の一つです。また、世界的に新生児の先天奇形や遺伝子異常の有病率が増加しています。これは、医療産業の繁栄とともに、市場の成長を後押ししています。さらに、従来の方法と比較して、高い精度と正確さ、痛みの少なさ、迅速な診断といった様々な利点があるため、非侵襲的な出生前スクリーニング方法に対する需要の高まりが、市場にプラスの影響を与えています。これに加えて、出生前・新生児遺伝子検査の利点に関する個人の意識の高まりは、業界の投資家に有利な成長機会を提供しています。さらに、健康志向の個人の増加による出生前・新生児遺伝子検査に対する需要の高まりが、市場の成長に寄与しています。これとは別に、各国の政府機関は、市民に充実したヘルスケア・サービスを提供するため、ヘルスケア・インフラの改善に注力しています。これに伴い、主な企業は患者の円錐角膜やその他の角膜ジストロフィーのリスクを特定するための遺伝子眼科検査を開発しています。さらに、遺伝性疾患のリスクを検出するための母体血漿中の無細胞DNA検査に対する需要の高まりは、良好な市場見通しをもたらしています。
The global prenatal and newborn genetic testing market size reached US$ 5.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.2 Billion by 2028, exhibiting a growth rate (CAGR) of 13.3% during 2022-2028. The growing demand for advanced diagnostic and screening devices, rising prevalence of congenital malformations and genetic abnormalities in newborn babies around the world, and thriving medical industry represent some of the key factors driving the market.
Prenatal and newborn genetic testing comprises blood tests, a specific type of ultrasound, and prenatal cell-free DNA screening that offers invaluable insights into the genetic makeup of unborn babies and newborns. It can identify certain birth defects, many of which are genetic disorders in unborn or newborn babies. It provides critical information to expectant parents, healthcare professionals, and researchers, enabling them to make informed decisions about the health and well-being of infants. It assists in improving patient outcomes and guiding medical interventions while enabling accurate identification of genetic variations and abnormalities during pregnancy and early infancy. It also aids in detecting various congenital conditions, such as Down syndrome, cystic fibrosis, sickle cell disease, and phenylketonuria. As it helps analyze various protein levels in the blood of parents to determine the risk for abnormal chromosome numbers in babies, the demand for prenatal and newborn genetic testing is rising across the globe.
At present, the rising demand for advanced diagnostic and screening devices among the masses across the globe represents one of the key factors supporting the growth of the market. In addition, there is an increase in the prevalence of congenital malformations and genetic abnormalities in newborn babies worldwide. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the growing demand for non-invasive prenatal screening methods due to their various benefits, such as high accuracy and precision, less pain, and fast diagnosis, as compared to conventional methods, is positively influencing the market. Besides this, the rising awareness among individuals about the benefits of prenatal and newborn genetic testing is offering lucrative growth opportunities to industry investors. Additionally, the escalating demand for prenatal and newborn genetic testing due to the increasing number of health-conscious individuals is contributing to the growth of the market. Apart from this, governing agencies of various countries are focusing on improving healthcare infrastructure to provide enhanced healthcare services to citizens. In line with this, key players are developing genetic eye tests to identify the risk of keratoconus and other corneal dystrophies in patients. Furthermore, the growing demand for cell-free DNA in maternal plasma tests to detect the risk of genetic disorders is offering a favorable market outlook.
IMARC Group provides an analysis of the key trends in each segment of the global prenatal and newborn genetic testing market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product type, screening, disease, and end user.
Consumables
Instruments
The report has provided a detailed breakup and analysis of the prenatal and newborn genetic testing market based on the product type. This includes consumables and instruments. According to the report, consumables represented the largest segment.
Non-invasive Prenatal Testing
Chorionic Villus Sampling
Amniocentesis
Maternal Serum Screening
A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the screening has also been provided in the report. This includes non-invasive prenatal testing, chorionic villus sampling, amniocentesis, and maternal serum screening. According to the report, non-invasive prenatal testing accounted for the largest market share.
Downs Syndrome
Phenylketonuria
Cystic Fibrosis
Sickle Cell Anemia
A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the disease has also been provided in the report. This includes downs syndrome, phenylketonuria, cystic fibrosis, and sickle cell anemia. According to the report, downs syndrome accounted for the largest market share.
Hospital
Maternity and Specialty Clinics
Diagnostic Centers
A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the end user has also been provided in the report. This includes hospital, maternity and specialty clinics, and diagnostic centers. According to the report, hospital accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for prenatal and newborn genetic testing. Some of the factors driving the North America prenatal and newborn genetic testing market included the growing number of pregnant women undergoing genetic screening, rising awareness about various inborn genetic diseases, enhanced healthcare infrastructure, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global prenatal and newborn genetic testing market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, BGI Group, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Ravgen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.